Drug R&D cost study
Executive Summary
Tufts University Center for the Study of Drug Development research associate Joseph DiMasi, PhD, will be the lead author of a benchmark study on drug R&D costs being prepared by the center. An adjunct assistant professor in economics at Tufts, DiMasi has been working on the study for over two years. A story in "The Pink Sheet" (Jan. 1, p. 3) on a preview of the study given at a recent IoM seminar by Duke University's Henry Grabowski, PhD, another of the study's investigators, inadvertently omitted DiMasi's name. The study, which estimates that the average cost of bringing a new drug to market now exceeds $200 mil., is expected to be ready for publication in "a couple of months".
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.